The period in brief – financial summary for the first quarter 2025 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 11,1 million (SEK 11,4 million). Operating loss for the quarter amounted to...
Read MoreIn connection with the upcoming financial interim report for the first quarter 2025, Kancera AB (publ) (Kancera) provides an update on the ongoing collaboration with Recardio Inc. and the company’s clinical development program and reports that Kancera: conducts joint...
Read MoreKancera AB (publ) reports that the last patient has completed the last visit in the ongoing phase Ib/IIa study KANDOVA evaluating the candidate drug KAND567 in ovarian cancer.
Read MoreKancera AB (publ) has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will take over as Certified Adviser on April 1, 2025.
Read MoreKancera signs letter of intent agreement with US biotech company, Recardio Inc., with the intention to out-license its fractalkine program, including drug candidates KAND567 and KAND145 Recardio’s phase III ready dutogliptin program and Kancera’s fractalkine program in phase II...
Read More